MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.lungcan.2022.08.018

Медицинская библиотека · Lung cancer (Amsterdam, Netherlands) · 2022

Early change in the clearance of pembrolizumab reflects the survival and therapeutic response: A population pharmacokinetic analysis in real-world non-small cell lung cancer patients.

Ohuchi Mayu, Yagishita Shigehiro, Jo Hitomi, Akagi Kazumasa, Inaba Higashiyama Ryoko, Masuda Ken, Shinno Yuki, Okuma Yusuke, Yoshida Tatsuya, Goto Yasushi, Horinouchi Hidehito, Makino Yoshinori, Yamamoto Noboru, Ohe Yuichiro, Hamada Akinobu

СтатьяПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

OBJECTIVES

The dosing pattern of pembrolizumab is based on population pharmacokinetic (Pop-PK) analysis of clinical trials. Data for Japanese patients or patient populations with poor conditions such as cachexia are scarce. In this study, we performed a Pop-PK analysis of Japanese non-small cell lung cancer patients and analyzed the relationship between exposure, treatment effect, and survival.

MATERIALS AND

METHODS

A total of 270 blood samples from 76 patients who received 200 mg pembrolizumab every 3 weeks between March 2017 and December 2018 were included. Blood concentrations of pembrolizumab were measured using mass spectrometry, and Pop-PK analysis was conducted using the Phoenix NLME software with a one-compartment model.

RESULTS

The estimated median of clearance (CL) in this analysis population was 0.104 L/day, about half of the historical data for Western data. Overall, pembrolizumab CL decreased over time, with some populations showing increased CL early in the treatment and others showing decreased CL over time. When the time-varying CL was stratified by quartile, the group with decreasing CL showed significantly better treatment response and survival than the group with increasing CL, even though the group included more patients with cachexia. Detailed analysis suggested that the patient population that responded to pembrolizumab treatment had an improved general condition and reduced protein catabolism, further decreasing CL.

CONCLUSION

In populations that benefit from pembrolizumab treatment, CL may be reduced early in their treatment, which may be a predictive and prognostic factor. However, further prospective validation of our findings is needed.

Для цитирования: Ohuchi Mayu, Yagishita Shigehiro, Jo Hitomi, Akagi Kazumasa, Inaba Higashiyama Ryoko, Masuda Ken, Shinno Yuki, Okuma Yusuke, Yoshida Tatsuya, Goto Yasushi, Horinouchi Hidehito, Makino Yoshinori, Yamamoto Noboru, Ohe Yuichiro, Hamada Akinobu. Early change in the clearance of pembrolizumab reflects the survival and therapeutic response: A population pharmacokinetic analysis in real-world non-small cell lung cancer patients.. Lung cancer (Amsterdam, Netherlands). 2022. DOI: 10.1016/j.lungcan.2022.08.018.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.